The use of amplitude-integrated electroencephalography (aEEG) for research and clinical use in the newborn infant has increased over the last 2 decades. However, with this increased use, concerns have been expressed about (1) the accuracy and reliability of the interpretation of aEEG by neonatal clinicians and (2) the lack of evidence of benefit from aEEG monitoring for the infant.1 As early as 1994, Greisen2 noted that lack of knowledge of whether and when to act on the information obtained with aEEG, rather than the technology itself, limited the usefulness of this technique in the newborn. The aims of this commentary are to address these concerns by first reviewing the historical context in which the aEEG was developed and then summarizing current evidence on the use of aEEG in the newborn. aEEG is not a new technology. The cerebral function monitor (CFM) was devised by Dr Douglas Maynard and its clinical potential was explored by Dr Pamela Prior in the 1960s as a means of monitoring cerebral function in adults undergoing bypass surgery and after resuscitation.3,4 With its time-compressed output, the CFM provided a simpler and cheaper means of following trends in cerebral function in the ICU and the operating room without the need for experienced technicians for application, voluminous recordings, and expertise in interpretation for the, then, analog conventional EEG systems. The electrode placement over the parietal areas (P3–P4 in the 10–20 system) was designed so as to be in close proximity to the vulnerable “watershed” regions of the brain in the border zones of arterial blood supply from all 3 cerebral arteries. This position also minimized artifacts from sweating, muscle activity, and eyelid … Address correspondence to Divyen K. Shah, MB, ChB, Washington University, Department of Pediatrics, 8th Floor, NW Tower, 1 Children's Place, St Louis, MO 63110. E-mail: shah_d{at}kids.wustl.edu
Read full abstract